Authors
Perla R Colunga-Pedraza, Alejandra De Las Fuentes-Cepeda, Héctor Alejandro Vaquera Alfaro, Luisa C Campos-Gonzalez, Alia Guadalupe Ordóñez Ayala, Carlos Emir Córdova Lucio, Laura Korin, Guilherme Fleury Perini, Luis Mario Villela Martínez, David Gómez-Almaguer, Henry Idrobo, Juan Rangel-Patiño, Myrna Candelaria, Denisse Castro, Brady Beltran, Fabiola Valvert, Ana Carolina Oliver, Camila Peña, Maria Alejandra Torres Viera, Alana von Glasenapp, Alfredo Quiroz, Rosa Rios Jimenez, Macarena Roa, Rosio Baena Terán, Luis Malpica
Published in
JCO global oncology. Volume 12. Issue 11. Pages e2600266. Epub Nov 12, 2026.
Abstract
The integration of diagnostic tools, immunochemotherapy, targeted agents, and cellular therapies such as chimeric antigen receptor T-cell therapy (CAR-T) cells has transformed lymphoma outcomes in high-income countries. However, in Latin America (LATAM), access to these advances remains limited. This study aimed to assess lymphoma care access and institutional capacity in LATAM.
We conducted a cross-sectional digital survey from July 2025 to August 2025, coordinated by the Grupo de Estudio Latinoamericano de Linfoproliferativos network. The survey captured center-level data covering infrastructure, human resources, diagnostic and therapeutic availability, and clinical research activity. Data were analyzed using descriptive methods.
A total of 73 hematology centers from 16 Latin American countries completed the survey. Most centers were public institutions (53%), with a median number of four hematologists per center (range, 2-10). While basic pathology and flow cytometry were widely available, access to advanced diagnostics was limited. Fifteen centers (21%) lacked immunohistochemistry, and pathology turnaround times exceeded 3 weeks in 56%. Positron emission tomography-computed tomography was available in 41% of centers. Novel therapies such as antibody-drug conjugates, bispecific antibodies, and checkpoint inhibitors were not available or restricted in most centers. Hematopoietic stem-cell transplantation was performed in 41% of centers, whereas commercial CAR-T was available in 5%. Clinical trials were conducted in 34% of centers.
Our findings highlight striking disparities between guideline-recommended lymphoma care and real-world institutional capacity across LATAM, underscoring the importance of collaborative efforts in building capacity and advocating for equitable access.
PMID:
43019500
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0